Please assess the completion status of the following clinical trial:

Trial Title: Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Treatment Group~Inclusion Criteria:~1. Subjects with known history of MDD verified using the Mini International Neuropsychiatric Interview and a Hamilton Depression Rating Scale 17-item score of at least 18~2. Subjects must have failed to respond to one previous adequate dose-duration trial of antidepressant therapy~3. Must complete the MRI screening tool and demonstrate ability to receive an MRI~4. For entry into the ARP augmentation phase the subject must be a non-responder to the escitalopram phase as demonstrated by a MADRS score at week 10, that is not reduced by greater than 50% from baseline.~Exclusion Criteria:~1. Subjects cannot be smokers~2. No significant history of anxiety disorder~3. Cannot be pregnant or lactating and sexually active women of childbearing potential must use a medically accepted means of contraception~4. The following DSM-IV diagnoses are excluded: Organic mental disorder; substance abuse/dependence, including alcohol, active within the last year; schizophrenia, paranoid or delusional disorders; other psychotic disorders; panic disorder; generalized anxiety disorder; obsessive-compulsive disorder, or post-traumatic stress disorder; bipolar disorder; bulimia nervosa; anorexia nervosa~5. Subjects with serious suicidal risks~6. Subjects who have taken any antidepressant medication other than escitalopram within 5 half lives, of the most recent antidepressant taken~7. Subjects involved in any other form of treatment for depression~8. Subjects who have demonstrated any previous inadequate antidepressant response to electroconvulsive therapy (ECT)~9. Subjects who have received ECT for the current depression episode~10. Subjects who have been hospitalized within 4 weeks of the study~11. Subjects who have received treatment with a monoaminoxidase inhibitor within 2 weeks of enrollment~12. Subjects with a known allergy, hypersensitivity, or previous unresponsiveness to aripiprazole or known intolerance to any study medications~13. Subjects with a history of participation in any investigational medication trial in the past month~14. A positive drug screen or substance use disorder in the past 12 months~15. History of any thyroid pathology~16. History of serotonin syndrome or neuroleptic malignant syndrome~17. History of seizure disorder~18. Subjects who have participated in a trial using PET scans in the past 12 months and in any trial in the past 30 days.~Control Group~Inclusion Criteria:~1. Ages 18-55 matched to a study subject~2. Must be a healthy subject with no significant medical history~3. Must complete the MRI screening tool and demonstrate ability to receive an MRI~Exclusion Criteria:~1. Cannot be a smoker~2. Cannot be pregnant or lactating and sexually active women of childbearing potential must use a medically accepted means of contraception~3. Any DSM-IV or II diagnosis as assessed by the MINI~4. Subjects with a positive drug screen or substance use disorder in the past 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Depressed Participants (Type: ACTIVE_COMPARATOR): Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment.
- Control Participants (Type: NO_INTERVENTION): Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.

Based on this trial design, predict the completion outcome and termination type (if applicable).